Mobile App

Google Play Apple Store
Treatment Progress in Triple Negative Breast Cancer – Improving Disparities and Outcomes with New Approaches
AMA/ANCC/ACPE Activity
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis. New and emerging agents may fulfill an unmet need for patients with TNBC. Rapidly evolving evidence in TNBC can present challenges in aligning practice with the latest clinical data and guideline recommendations. This virtual roundtable conversation is designed to provide learners with the opportunity to enhance clinical decision-making skills about the diagnosis and management of TNBC. Participants will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care. Faculty will also discuss new strategies and approaches to reduce breast cancer mortality and improve the health outcomes of racial/ethnic groups.
Review the activity and claim AMA/ANCC/ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.




GWilliam Gradishar, MD William Gradishar, MD
Chief of Hematology and Oncology in the Department of Medicine
Betsy Bramsen Professor of Breast Oncology
Professor of Medicine (Hematology and Oncology)
Northwestern University Feinberg School of Medicine in Chicago

Yuan Yuan, MD Yuan Yuan, MD
Director, Breast Cancer Research
Clinical Professor, UCLA
Cedars-Sinai Medical Center

 Rita Nanda, MD Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine

20
Supported by an independent educational grant from
AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC

Launch Date:November 2, 2023
Release Date: November 2, 2023
Expiration Date: October 31, 2024

October 31, 2024
Mini Module
7646
TNBC(1150x108)_conversations.png
Hematology-Oncology